By triggering an adaptive response to hypoxia which is a common feature of tumor microenvironments, endothelial cells contribute to the onset of angiogenic responses involved in tumor growth. Therefore, identifying hypoxic markers represent a challenge for a better understanding of tumor angiogenesis and for the optimization of anti-angiogenic therapeutic strategy. Using Representational Difference Analysis combined with microarray, we here report the identification of 133 hypoxia-induced transcripts in human microendothelial cells (HMEC-1). By Northern Blot, we confirm hypoxia-induced expression of Insulin-like growth factor binding protein 3 (igfbp3), thioredoxin-interacting protein (txnip), neuritin (nrn1). Finally, by performing in situ hybridization on several types of human tumors, we provide evidence for nrn1 and txnip as hypoxic perinecrotic markers and for igfbp3 as a tumor endothelial marker. We propose these hypoxia-induced genes could represent relevant prognostic tools and targets for therapeutic intervention in cancers.
Introduction:
By exercising control over gene transcription, hypoxia is a common feature of several human pathologies, including cardiovascular diseases and cancer. In solid tumors, the balance between cell proliferation and oxygen supply is affected, leading to a decrease in oxygen partial pressure (pO2) [1] .
Hypoxic cells trigger an adaptative molecular response to modulate expression of many genes in order to allow better perfusion and (pO2) increase in tumor tissue. Hypoxia-induced gene expression is under the control of key-transcription factors, the Hypoxia-Inducible Factors (HIFs) [2] , involving posttranslational modifications of the -subunit which determine both half-life and transcriptional activity on target genes [3, 4] .
Angiogenesis promotes not only tumor growth, but also progression from a pre-malignant to a malignant and invasion tumor phenotype. In the tumor microenvironment, hypoxia appears to target a multiplicity of cell types which participate in tumor progression and endothelial cells are widely involved in tumor angiogenesis. In this context, targeting the tumor vasculature to « normalize » it [5] temporarily or to eradicate it completely seems to be a promising anti-cancer therapeutic strategy [6] .
To this aim, gene expression profiles of tumor cells [7] but also of endothelial cells in response to hypoxia were characterized by using microarray technologies or differential screening techniques [8] [9] [10] [11] . However, new markers are needed for a better understanding of the hypoxia-induced angiogenesis in tumors and for the development of new diagnostic, prognostic and therapeutic tools in cancer [8] .
Here, we first report a novel repertoire of hypoxia-induced transcripts (HITs) in human microendothelial cells HMEC-1 using mRNA differential screening by cDNA Representational Difference Analysis (cDNA RDA) [12] and cDNA microarray. We then described mRNA expression of HITs, particularly Neuritin (nrn1), Thioredoxin-interacting protein (txnip) and Insulin-like growth factor binding protein 3 (igfbp3), in various types of human tumors. Based on these observations, we therefore propose these HITs might represent relevant prognostic tools and targets for therapeutical intervention in cancers.
-4 -differential expression between the two populations of cells was performed using the limma R package [20] . False discovery rate (FDR) correction was applied to take into account multiple testing hypotheses. Significance levels were set to p<0.05 and p<0.01. Genes below these thresholds were considered significantly differentially expressed.
Northern Blots were performed using NorthernMax kit from Ambion. Briefly, 20µg/lane of total RNA was fractionated by 1% denaturing gel electrophoresis and transferred to nylon membranes (Hybond N + ; Amersham Biosciences). The blots were hybridized with 32 P-labeled cDNA probes (Random Primer DNA Labeling System ; Invitrogen) overnight at 42°C in the UltraHyb solution (Ambion).
Paraffin section preparation, probe labeling by in vitro transcription, and in situ hybridization were performed as previously described [14] .
Immunohistochemistry
Immunostaining with a polyclonal goat anti-human IGFBP3 (1/50; R&D Systems AF675) antibody was performed by routine methods using a biotinylated secondary antibody and the ABC-peroxidase complex (Vector Laboratories) with diaminobenzidine-H 2 O 2 used as the chromogen for detection.
Results and Discussion:
In order to identify genes whose expression is induced by hypoxia in endothelial cells, we In order to further confirm hypoxia induction, we performed Northern Blot analysis on HMEC-1 and HUVEC cultured in hypoxic conditions, specifically for the pro-apoptotic gene igfbp3, the tumor and metastasis suppressor gene txnip and the firstly described hypoxia-induced gene neuritin1 (nrn1). Normalization of the genes of interest to a housekeeping gene, such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH), -actin or cyclophilin could not be performed here since the fact that steady-state levels of these control genes cannot be assumed in endothelial cells exposed to DFO or 2% hypoxia. Therefore, the amounts of RNA loaded were normalized by hybridization with a 28S-specific probes which is known to be a constant fraction of total RNA. We observed hypoxia-induced expression of these 3 genes in both endothelial cell types, namely HMEC-1 and HUVEC, subjected to chemical hypoxia compared to normoxia, as previously shown for angptl4 [14] , used as a control here. Lowering oxygen concentration also induced expression of igfbp3 and nrn1 in both HMEC-1 and HUVEC while level of expression was less important than using DFO. respectively and have iron (Fe 2+ ), 2-oxoglutarate and dioxygen as co-substrates [4] .
Given that both tumor and vascular cells were shown to be hypoxic in tumors, we then studied the expression of these HITs in various types of human cancers with the aim to characterize new tumor and/or tumor endothelial markers. In the present study, we focused on nrn1, txnip and igfbp3 for which no or only few data were available concerning their in situ mRNA expression in cancers.
Neuritin, also called CPG15, is a GPI-anchored protein which was reported to be weakly expressed in human kidney, heart, spleen, lung [21] . Neuritin is also expressed in the liver and is well correlated to the maturation of hepatocytes [22] as well as in neuronal structures associated with plasticity in the adult [21] . NRN1 has been largely involved in neuritogenesis and was shown to promote dendritic growth [23] and the development of motor neuron axon arbors [24] . In this study, we demonstrated that nrn1 gene is expressed and induced by hypoxia in ECs. Neuritin could therefore belong to the increasing family of axon guidance which could be implicated in vessel pathfinding and network formation as recently shown for several of these molecules [25] . To the best of our knowledge, nrn1 mRNA expression has never been described in human biopsies from normal or tumor tissues. Here, by performing in situ hybridization experiments, we examined nrn1 mRNA expression in different human tumors such as colon and prostate tumors, renal cell carcinoma and glioblastoma. Nrn1 is expressed in both tumor and normal epithelial cells and weakly in endothelia of blood vessels of normal and tumoral areas in colon and prostate (data not shown). For the first time,
we showed that nrn1 mRNA is reproducibly highly expressed in a restricted number of tumor cells around perinecrotic regions of conventional RCC (figure 2: a-c) and glioblastoma (figure 2: d-f),
regions in which hypoxia has been reported to up-regulate gene expression [26] . We did not detect nrn1 expression in peritumoral areas of these two types of tumor (data not shown). Furthermore, NRN1 has recently been implicated in tumorigenesis by promoting changes in cell morphology, anchorage-independent growth and tumor formation [27] . In this context, the fact that hypoxic tumor cells highly express neuritin makes this molecule an attractive candidate as a hypoxic tumor marker and a potential target for therapeutic intervention in cancers.
Thioredoxin-interacting protein is interacting and negatively regulating thioredoxin [28] and is involved in suppression of tumor growth [29] . Furthermore, in an in vitro model of intravasation, overexpression of TXNIP by infecting melanoma cells with adenovirus increased transendothelial migration 3-fold versus control [30] . Until now, txnip mRNA was reported to be downregulated in various human tumors, including breast, stomach and lung [29] and gastrointestinal cancers [31] . For the first time, we provide evidence for txnip overexpression in tumor cells of hypoxic perinecrotic areas of conventional RCC (figure 2: g-i) and glioblastoma (figure 2: j-l) compared to non-hypoxic tumor cells and peritumoral tissues. Furthermore, hypoxia is often associated with increased metastasis and poor prognosis in cancer. Therefore, txnip might represent a valid candidate as prognostic marker and therapeutic target for anti-metastatic treatment.
We also studied IGFBP3 expression, which is shown to have anti-IGF-1 and IGF-1-independent pro-apoptotic activities. Many studies have provided evidence for the in vitro induction of igfbp3 mRNA by hypoxia in different cell types, including ES cells [32] , tumor cells [7, 33] and ECs [9, 11, 34] . In vivo, a marked increase of igfbp3 mRNA was reported in the endothelium of human corpus luteum during early phase of luteal development which is accompanied by extensive angiogenesis [35] and specifically in tumor endothelial cells of a murine breast cancer model [36] . We here provide evidence for an igfbp3 mRNA expression in intratumoral ECs of colon carcinoma (figure 3: a-c), whereas tumor and normal epithelial cells of the colon don't express igfbp3 mRNA (data not shown). Concerning prostate, we showed that igfbp3 is also very highly expressed in the ECs of adenocarcinoma ( figure 3: d-f) . We also demonstrated that igfbp3 mRNA is specifically produced by
ECs of tumor blood vessels in conventional RCC classified as pT1 in tumor, node, metastasis (TNM)
system. In contrast, to draw a conclusion from results obtained in patients with pT2 and pT3
conventional RCC is more difficult. Indeed, igfbp3 mRNA is produced only by tumor cells in some reverses proliferation and prevents the survival induced by VEGF in HUVEC [38] and that downregulation of endothelial igfbp3 mRNA by Runx1 transcription factor promoted angiogenesis in the matrigel assay [39] . However, IGFBP3 functions in tumor-associated angiogenesis are not understood yet and have to be examined thoroughly in order to evaluate IGFBP3 suitability as a valid therapeutic target. The present study compared nrn1, txnip and igfbp3 mRNAs expression in tumor and peritumoral area. Data concerning the expression of these genes in human biopsies from normal organs (kidney, colon, prostate) are lacking in the litterature. Therefore, more detailed gene expression analyses have to be performed on normal tissues to fully consider nrn1, txnip and igfbp3 as proper tumor markers.
Altogether, this work provided evidence for a new set of hypoxia-induced genes in ECs in vitro. Overexpression of some of these genes was further observed in different cell types subjected to in vivo pathological hypoxia, particularly in tumor cells surrounding necrotic regions or tumor endothelial cells. In this context, we propose these genes, txnip, nrn1 and igfbp3 as hypoxic markers and potential makers in tumor angiogenesis, might become prognostic tools and potential anticancerous therapeutic targets. 
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